TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include treatment with insulin or thiazolidinediones \[i.e., peroxisome proliferator activated receptor-gamma, PPARγ agents\])~* male or a female of non-childbearing potential. Women must be postmenopausal or premenopausal and documented surgically sterilized~* A body mass index (BMI) that is \> 20 and ≤ 40 kg/m2~Exclusion Criteria:~* History of type 1 diabetes or assessed by the investigator as possibly having type 1 diabetes~* History of ketoacidosis; clinically unstable or rapidly progressive diabetic retinopathy, nephropathy, neuropathy~* Treatment for diabetes within 3 months of study participation with combination anti-hyperglycemic therapy, insulin or thiazolidinediones (e.g., rosiglitazone or pioglitazone)~* oral corticosteroid medications within 2 weeks prior to study participation, or requires digoxin, warfarin, warfarin-like anticoagulants, theophylline, anti-dysrhythmic or anti-seizure medications, immunosuppressants, or anti-neoplastic agents, or herbal remedies~* History of acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)~* History of gastrointestinal problems or disorders or extensive bowel or gastric surgery~* History of significant or unstable cardiovascular disease~* History of neoplastic disease~* History of hepatic disease~* History of seizures, epilepsy or other neurologic disease~* History of myelodysplastic or pre-leukemic disorders or other severe hematological disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-0893 (40 mg) (Type: EXPERIMENTAL): MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
- MK-0893 (120 mg) (Type: EXPERIMENTAL): MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
- Metformin (2000 mg) (Type: ACTIVE_COMPARATOR): Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching the MK-0893 and placebo tablets matching metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Infants born 18 - 20 weeks prior to the first round of the 2002 National Immunization Days in cuba (in March 2002).~Born healthy at one of the 4 designated maternity hospitals in Cuba~Exclusion Criteria:~Serious congenital defect/disease at birth~-

- Gender: MALE
- Minimum Age: 6 Weeks
- Maximum Age: 2 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Personalized Risk Estimator for Rheumatoid Arthritis Family Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* First degree blood relative (parent, sibling, or child) with diagnosis of RA~* Age between 18 and 70 years old~Exclusion Criteria:~* Non-English speaking~* Sign/symptoms of rheumatoid arthritis (assessed by screening questionnaire and study staff)~* Rheumatoid arthritis~* Systemic lupus erythematosus~* Juvenile Idiopathic Arthritis~* Psoriatic Arthritis~* Ankylosing Spondylitis~* Mixed Connective Tissue Disease~* Reactive Arthritis~* Adult-Onset Still's Disease~* Sjogren's Syndrome~* Dermatomyositis~* Polymyositis~* Polymyalgia Rheumatica~* ANCA-associated Vasculitis~* Giant Cell Arteritis~* Polyarteritis Nodosa~* Behcet's Disease~* Relapsing Polychondritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- General Rheumatoid Arthritis Education (Type: ACTIVE_COMPARATOR): Arm 1 participants will receive general information about RA.
- PRE-RA (Type: EXPERIMENTAL): Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
- PRE-RA Plus (Type: EXPERIMENTAL): Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a diagnosis of T2DM and be currently treated with metformin IR~* Patients in the study must have a HbA1c between \>=7 and \<=10.5%~* Patients must have a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
- Placebo/Sitagliptin (Type: OTHER): Each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin will be given with protocol-specified doses of metformin immediate release.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sevoflurane, Propofol, and Sevoflurane Plus Propofol for Maintenance of Anaesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status class 1 or 2~* Aged \>=18 years and =\<40 years old~* Suffering from infertilities~* Under elective gynaecological laparoscopic and hysteroscopic surgery~Exclusion Criteria:~* ASA-PS\>=III~* Aged under 18 yrs or above 40 yrs old~* Body mass index (BMI) \>30~* Respiratory or Neurologic disease~* Chronic antidepressants and Anticonvulsant drugs~* Chronic analgesics intake~* A known allergy to the drugs being used~* History of substance abuse~* Participating in the investigation of another experimental agent~* Participating in the investigation of another study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: EXPERIMENTAL): anesthesia maintenance with propofol and remifentanil
- Sevoflurane (Type: EXPERIMENTAL): Sevoflurane and Remifentanil for anesthesia maintenance
- Sevoflurane+Propofol (Type: EXPERIMENTAL): Sevoflurane+Propofol for anesthesia maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ductal Lavage Versus Corticosteroids Therapy for Idiopathic Granulomatous Mastitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, age between 18 and 65 years old.~* Inform consent signed.~* Clinical diagnosis of non-lactating mastitis, defined as mastitis occurred more than 1 month after the cessation of lactation.~* Clinical and pathological diagnosis of idiopathic granulomatous mastitis.~* Never receive surgical treatments, or corticosteroids therapy after the cessation of lactation. Core needle biopsy is allowed.~* Good health, judged by clinicians, to receive ductal lavage.~* M score \>=2~Exclusion Criteria:~* Grade III inverted nipple(Plastic. Reconstruction. Surgery. 104: 389, 1999.)~* Lactational mastitis patients.~* Bilateral IGM patients.~* Clinically diagnosis of periductal mastitis.~* Pathological diagnosis of breast carcinoma.~* Pregnant women.~* Evidences suggest possible diagnosis of SLE(systemic lupus erythematosus), rheumatic disorders or other systematic auto-immune diseases.~* Evidences suggest possible diagnosis of tuberculosis.~* Evidences suggest possible diagnosis of fungus infection of the breast~* History of breast trauma.~* History of taking oral corticosteroids or anti-tuberculosis treatment.~* Imaging examinations indicates foreign objects retained in the breast~* Presence of sepsis or severe inflammation caused by IGM, for which surgery is likely required.~* Patients with inappropriate coagulation function, cardiac function, pulmonary function, liver and renal function, that clinicians judges as not suitable to participate in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ductal lavage (Type: EXPERIMENTAL): Ductal lavage and breast massage for two weeks.
- Corticosteroids therapy (Type: ACTIVE_COMPARATOR): Oral corticosteroids therapy for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 20 years at the time of informed consent~* Japanese patients with type 2 diabetes~* Patients who have HbA1c ≥ 7.0% and \< 10.0% if untreated with antidiabetic agent.~* Patients who have HbA1c ≥ 6.5% and \< 9.5% if treated with antidiabetic agent.~Exclusion Criteria:~* Patients aged ≥ 70 years at the time of informed consent~* Patients with a history of type 1 diabetes or diabetic ketoacidosis~* Patients receiving or requiring treatment with insulin~* Patients with a body mass index (BMI) of \< 18.5 kg/m2 or ≥ 35.0 kg/m2~* Patients with an estimated glomerular filtration rate (eGFR), \< 45 mL/min per 1.73 m2~* Patients with fasting plasma glucose ≥ 240 mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- DS-8500a 10mg once daily (Type: EXPERIMENTAL): 10mg DS-8500a tablet given orally once daily
- DS8500a 75 mg once daily (Type: EXPERIMENTAL): 75mg DS-8500a tablet given orally once daily
- placebo to match DS-8500a tablet (Type: PLACEBO_COMPARATOR): placebo matching DS-8500a tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients who will undergo elective hip or knee arthroplasty.~Exclusion Criteria:~* Exclusion criteria must be read in conjunction with the local product information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None
- Group 2 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have been treated with hESC-RPE cell transplant in the core protocol.~* Able to understand and willing to sign the informed consent to participate in the follow up study.~Exclusion Criteria:~- There are no exclusion criteria.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MA09-hRPE (Type: None): Experimental: Subretinal injection of MA09-hRPE~* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amlodipine 10mg Drug Use Investigation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects who have been treated with amlodipine 5mg at least 4 weeks~* The subjects who had not achieved target BP~Exclusion Criteria:~* Subjects who have been prescribed amlodipine (Norvasc®) 10mg Tablet before

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amlodipine 10mg Tablet (Type: None): Subjects taking Amlodipine 10mg Tablet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* has a negative clinical history for varicella and herpes zoster~* females of reproductive potential have a negative pregnancy test prior to each study vaccination~* females of reproductive potential remain abstinent or use 2 acceptable methods of birth control during study until 3 months following last study vaccination~* females not of reproductive potential do not require a pregnancy test or use of contraceptives~* legal representative of adult or parent of children understands risks involved with, consent to participate in, and comply with the study procedures~Exclusion Criteria:~* has a history of allergy or anaphylactic reaction to neomycin, gelatin, or any component of VARIVAX\^TM~* has received any form of varicella or herpes zoster vaccine at any time prior to study, or anticipates receiving any during study~* has received immune globulin, a blood transfusion or blood derived products within prior 5 months or plans to do so during study~* has received aspirin or any aspirin-containing products within prior 14 days~* has been exposed to varicella or herpes zoster in the prior 4 weeks involving playmate, hospital or continuous household contact, or had contact with a newborn whose mother had chickenpox 5 days before or 2 days after delivery~* has, or lives with a person who has, any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity including those resulting from corticosteroid use or other immunosuppressive therapy~* has received glucocorticosteroids for more than 5 consecutive days within prior 3 months, or any dose of glucocorticoids within prior 7 days, or expects to use glucocorticosteroids during the study~* was vaccinated with licensed non-live or live vaccine within prior 30 days or expects vaccination during 42 day follow-up postvaccination period~* had a fever within 72 hours prior to study vaccination~* has participated in another trial within prior 30 days, is currently participating in another trial, or plans to participate in another trial during the planned study period for this trial~* is pregnant or nursing

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- VARIVAX™ (Type: EXPERIMENTAL): All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hemodialysis patients~* Age greater than or equal to 18~* Able and willing to give informed consent~* Undetectable Anti-HBs Ab level~Exclusion Criteria:~* Presence of hepatitis BsAg, hepatitis BcAb~* Treatment with IVIg (intravenous immune globulin) within the last 6 months~* Hypersensitivity to components of either vaccine~* Contraindication to intramuscular injections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18 years or older~* Complicated skin and skin structure infection (cSSTI)~* Infection of sufficient severity to warrant hospitalization~* Infection of sufficient severity such that it is expected to require at least 5 days of intravenous antibiotic therapy~Exclusion Criteria:~* Received systemic antibacterial drugs for greater than 24 hours within 96 hours prior to first dose of study drug~* Uncomplicated skin and skin structure infections, skin infections suspected to be caused by viral or fungal pathogens~* Diabetic foot infections, decubitus ulcers, ulcers due to peripheral vascular disease~* Infection caused by human or animal bites, sternal wound infections, bone infection or arthritis due to an infection, critical limb ischemia of the affected limb~* Chronic liver disease or severe impaired renal function, severe low white blood cell count, burns on greater than 15% of total body surface area, necrotizing skin infection, amputation required of primary site of infection, sustained shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Ceftaroline fosamil (Type: EXPERIMENTAL): Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
- Vancomycin plus aztreonam (Type: ACTIVE_COMPARATOR): Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete